Quality and Regulatory

GMP Annex 1 Implementation

Andrea Salmaso, Stevanato Group

News Brief: More FDA Guidances for the New Year

Walter Morris, PDA

Points to Consider When Applying QRM

Douglas Campbell, InterPro QRA

Biopharmaceutical Manufacturing Conference

Louise Uí Fhatharta, Pharmalex

The Latest Current FDA CBER Initiatives

Edward H. Trappler, Lyophilization Technology, Inc. and Denise Miller, Lyophilization Technology

Sprinting Toward the Lab of the Future: Practical Steps to Get Started

Ashley McMillan, Veeva Vault LIMS

Q&A on the Revised PDA Technical Report No. 22

Subrata Chakraborty, PhD, INOVR , Vanessa Figueroa, VVF Science , and Marcia C. Baroni, MBA, Emergent BioSolutions Inc

Microbial Ingress No Longer an Effective CCI Test Method

Oliver Stauffer, PTI and Tyler Harris, PTI

Understanding Japan Quality

Antonio Burazer, Takeda

PDA Manufacturing Meets Legislation

Dr. Bettine Boltres and Ana Marques Kuschel, PhD, WEST Pharmaceutical Services

The High Cost of Cheap Drugs

Martin VanTrieste, Civica Rx

News Brief: Navigating Regulatory Uncertainty

Justin Johnson, PDA

Validating NGS-Based Assays In-House for Virus Safety Assessment

Christoph Bredack, PhD, Genedata

Process Hold Times: What is it and Why is it Important?

Robert Dream, MS, Nivagen Pharmaceuticals and Bruce Loxley, GSK

New Training Course – Manage your Aseptic Filling Line

Julian Petersen, groninger & co. gmbh

Navigating the CDMO-Sponsor Partnership

Morten Munk, FUJIFILM Diosynth Biotechnologies , Virginia Boldt, Accenture , and Andrew Chang, PhD, PhD, Novo Nordisk

An Alternative and Sustainable BET Designed for Patient Safety

Parampal Deol, PhD, Charles River Laboratories

A Holistic Approach to CCI is a Deterministic Approach

Oliver Stauffer, PTI

Pathway to a Contamination Control Strategy

Londa Ritchey and Patrick Nieuwenhuizen, PharmaLex

FDA/CDER Readying Draft Guidance on AI to Support Regulatory Decision-Making

Justin Johnson and Walter Morris, PDA